Cytek Biosciences Inc
Company Profile
Business description
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Contact
47215 Lakeview Boulevard
FremontCA94538
USAT: +1 877 922-9835
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
702
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.60 | 8.90 | -0.10% |
| CAC 40 | 7,819.57 | 45.50 | -0.58% |
| DAX 40 | 25,239.85 | 209.34 | -0.82% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,501.87 | 39.82 | -0.38% |
| HKSE | 24,155.44 | 125.12 | -0.52% |
| NASDAQ | 27,599.89 | 122.58 | 0.45% |
| Nikkei 225 | 70,035.71 | 648.27 | -0.92% |
| NZX 50 Index | 13,684.04 | 16.08 | -0.12% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,727.70 | 8.00 | -0.09% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |